Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $160.5 million.

  • Prime Medicine's Shares Outstanding (Diluted Average) rose 34.02% to $160.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.5 million, marking a year-over-year increase of 34.02%. This contributed to the annual value of $118.6 million for FY2024, which is 30.37% up from last year.
  • Per Prime Medicine's latest filing, its Shares Outstanding (Diluted Average) stood at $160.5 million for Q3 2025, which was up 24.24% from $129.2 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Shares Outstanding (Diluted Average) registered a high of $160.5 million during Q3 2025, and its lowest value of $13.0 million during Q4 2021.
  • Over the past 3 years, Prime Medicine's median Shares Outstanding (Diluted Average) value was $118.6 million (recorded in 2024), while the average stood at $113.2 million.
  • Data for Prime Medicine's Shares Outstanding (Diluted Average) shows a peak YoY surged of 367.52% (in 2023) over the last 5 years.
  • Over the past 5 years, Prime Medicine's Shares Outstanding (Diluted Average) (Quarterly) stood at $13.0 million in 2021, then spiked by 161.23% to $33.9 million in 2022, then soared by 168.42% to $91.0 million in 2023, then soared by 30.37% to $118.6 million in 2024, then surged by 34.02% to $160.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $160.5 million in Q3 2025, compared to $129.2 million in Q2 2025 and $130.9 million in Q1 2025.